Overview
NAGE market data
Price History
NAGE price chart
Valuation & Profitability
- P/E (TTM)
- 13.59 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.17 – $11.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $253.3 · P/B 6.63 · P/S 1.94.
Company news
Niagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia TelangiectasiaBenzinga · Jul 13, 2026, 12:34 PM
Niagen Bioscience Files Prospectus To Offer And Sell Common Stock Up To $50MBenzinga · Jul 10, 2026, 9:20 PM
Niagen Bioscience Launches NAD Pharmaceuticals, Its Wholly Owned Subsidiary Focused On Developing Therapies For Accelerated Aging And Rare Genetic DiseasesBenzinga · Jul 8, 2026, 12:40 PM
Niagen Bioscience Officially Renames The ChromaDex External Research Program (CERP) To Niagen Research ProgramBenzinga · Jun 2, 2026, 12:45 PM
HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Lowers Price Target to $11Benzinga · May 11, 2026, 11:06 AM
8-K filing — Niagen Bioscience, Inc. (NAGE)SEC EDGAR · May 6, 2026, 8:01 PM